Report ID: SQMIG35H2340
Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the Proteomics Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading Proteomics industry players.
The global proteomics market is expected to be governed by a massive surge in demand for personalized medicine and advancements in mass spectrometry. Proteomics enables the identification of disease-specific biomarkers and therapeutic targets, allowing precise drug selection. Continuous improvements in mass spectrometry, chromatography, and electrophoresis have significantly enhanced protein identification, quantification, and analysis. These innovations provide greater sensitivity, resolution, and throughput, enabling more accurate proteome mapping.
According to SkyQuest Technology “Proteomics Market By Instrumentation Technology (Spectroscopy, Chromatography), By Reagent (Immunoassay Reagents, Spectroscopy Reagents), By Service, By Software, By Application, By End-User, By Region - Industry Forecast 2025-2032,” Global proteomics market is projected to grow at a CAGR of over 13.7% by 2032, as investments in biotechnology and gene technology R&D rises. Proteomic research helps uncover molecular mechanisms of diseases, enabling targeted drug design. Rising R&D budgets and collaborative research initiatives between industry and academia are boosting the adoption of proteomic technologies worldwide, fueling steady market growth.
|
Company |
Est. Year |
Headquarters |
Revenue |
Key Services |
|
Thermo Fisher Scientific |
1956 |
Waltham, Massachusetts, USA |
USD 42.87 billion (2024) |
Mass spectrometry, protein identification, reagents, analytical instruments, bioinformatics solutions |
|
Creative Diagnostics |
2005 |
New York, USA |
NA |
Antibody development, protein expression, proteomics assay kits, biomarker analysis |
|
Agilent Technologies |
1999 |
Santa Clara, California, USA |
USD 6.53 billion (2024) |
Chromatography systems, mass spectrometry, sample preparation, bioinformatics, proteomics workflows |
|
Bruker Corporation |
1960 |
Billerica, Massachusetts, USA |
USD 3.36 billion (2024) |
Mass spectrometers, NMR spectroscopy, protein characterization, imaging and omics solutions |
|
Danaher Corporation |
1984 |
Washington, D.C., USA |
USD 23.87 billion (2024) |
Life sciences tools, protein analysis, mass spectrometry, diagnostics, and bioprocessing |
|
Waters Corporation |
1958 |
Milford, Massachusetts, USA |
USD 2.95 billion (2024) |
LC-MS systems, proteomics software, biomolecule analysis, chromatography instruments |
|
Bio-Rad Laboratories |
1952 |
Hercules, California, USA |
USD 2.56 billion (2024) |
Protein electrophoresis, western blotting, chromatography, bioassay reagents |
|
PerkinElmer (Revvity Inc.) |
1937 |
Waltham, Massachusetts, USA |
NA |
Proteomics instrumentation, mass spectrometry, ELISA kits, sample preparation systems |
|
Creative Proteomics |
2005 |
Shirley, New York, USA |
NA |
Protein quantification, biomarker discovery, post-translational modification analysis, mass spectrometry services |
|
Promega Corporation |
1978 |
Madison, Wisconsin, USA |
NA |
Protein analysis kits, enzyme assays, protein-protein interaction tools, bioluminescent technologies |
This leading scientific instrumentation and life sciences solution provider plays a crucial role in advancing proteomics research around the world. Themo Fisher is known for offering a comprehensive suite of tools including Orbitrap™ mass spectrometers, sample preparation systems, reagents, and bioinformatics software. The company’s advanced analytical systems and cloud-based data analysis tools are widely used in clinical proteomics, enabling researchers to explore protein expression, post-translational modifications, and disease mechanisms.
This United States-based biotechnology company is known for its expertise in antibody development and proteomics assay solutions. Creative Diagnostics provides customized services for protein profiling, ELISA kit development, and protein expression systems. With strong R&D capabilities, the company supports academic, clinical, and pharmaceutical research by enabling accurate protein quantification, validation, and characterization for complex biological studies. The company offers an extensive range of proteins, peptides, antibodies, and diagnostic reagents to support proteomics and biomarker discovery.
Agilent Technologies is known for delivering cutting-edge proteomics workflows through its liquid chromatography (LC) and mass spectrometry (MS) systems, sample preparation tools, and bioinformatics software. The company’s high-resolution Q-TOF and triple quadrupole mass spectrometers are also extremely popular among researchers working in the field of proteomics. Agilent’s commitment to advancing data accuracy and workflow efficiency continues to accelerate proteomic discoveries globally, which makes it a key player in the global landscape going forward.
Bruker Corporation is a distinguished provider of analytical and diagnostic solutions with a strong focus on proteomics and structural biology. The company’s innovations in bioinformatics and data-driven molecular analysis have made it a cornerstone in modern proteomic studies. Bruker’s timsTOF™ and MALDI Biotyper™ platforms enable high-resolution protein identification and quantitative proteomics analysis. The company’s portfolio includes high-performance mass spectrometry systems, nuclear magnetic resonance (NMR) spectroscopy, and advanced imaging technologies.
Danaher is a key contributor in advancing proteomics R&D through its subsidiaries such as Cytiva, Sciex, and Beckman Coulter Life Sciences. The company’s emphasis on data-driven research enables researchers to explore complex protein interactions and expression patterns. Danaher is known for offering advanced tools for proteomics, protein analysis, and bioprocessing. Its continuous investment in innovation supports the advancement of precision medicine, proteomic-based diagnostics, and therapeutic development worldwide.
Waters Corporation is a renowned provider of analytical instruments and software for proteomics and life sciences research. Waters’ Synapt™ and Xevo™ systems deliver superior analytical sensitivity, enabling the study of complex proteomes. The company’s UNIFI™ software is also popular among proteomics researchers to integrate data processing for comprehensive protein analysis. The company’s ultra-performance liquid chromatography (UPLC) and high-resolution mass spectrometry (HRMS) platforms are essential for protein identification and quantification.
Bio-Rad is known for offering an expansive proteomics portfolio of protein electrophoresis systems, western blotting tools, chromatography media, and protein quantification reagents. The company is known to offer precision instruments that enable high-quality protein separation and identification, which is essential in proteomics. Its innovative assay kits and imaging systems support both basic and applied research in protein structure and function.
PerkinElmer (Revvity Inc.) is emerging as a top name in the proteomics industry owing to its portfolio of mass spectrometry instruments, ELISA kits, and sample preparation systems for protein characterization. The company also integrates automation and informatics for high-throughput proteomics research. With a focus on precision analytics and diagnostics, PerkinElmer plays a vital role in advancing biomedical research, drug development, and translational proteomics aimed at improving patient outcomes.
Creative Proteomics is a renowned name in the proteomics business known for offering comprehensive proteomics and metabolomics solutions. Creative Proteomics is known for its customizable workflows that meet the specific needs of academic and industrial clients. By combining high-quality instrumentation with expert bioinformatics, the company enables researchers to interpret complex proteomic data with precision and confidence. Its expertise in protein identification, quantification, post-translational modification (PTM) analysis, and biomarker discovery also ensures its leading stance.
Promega Corporation, founded in 1978 and headquartered in Madison, Wisconsin, is a leading provider of innovative life science tools for protein analysis and cellular research. The company’s proteomics portfolio includes enzyme assays, bioluminescent technologies, protein-protein interaction kits, and protein expression systems. Promega’s NanoLuc® and NanoBRET® platforms are widely used for studying protein interactions in live cells.
The global proteomics market is anticipated to expand at a robust CAGR but is expected to be hampered by high costs of instruments and reagents. Biomarkers are vital for early disease detection, prognosis, and treatment monitoring. Proteomics allows comprehensive analysis of proteins involved in disease mechanisms, making it instrumental for biomarker discovery. With rising demand for non-invasive diagnostics and predictive medicine, proteomics-based biomarker research is expanding, strengthening its role in clinical and pharmaceutical applications.
REQUEST FOR SAMPLE
The high instrumentation cost, complex workflows, and requirement for high throughput bioinformatics infrastructure limits access for the masses. Even the interpretation of data generated by proteomics studies requires specific expertise which limits widespread clinical use and integration with other omics methods across multiple mass spectrometry platforms.
Proteomics studies use technologies like mass spectrometry, chromatography, electrophoresis, and protein microarrays. The mass spectrometry and chromatography techniques have excellent sensitivity, provide excellent protein identification, and are necessary for the discovery of biomarkers applicable to personalized medicine.
Mass spectrometry is a high-resolution, high-sensitivity core technique in proteomics. It assists drug discovery and biomarker discovery, especially using tandem mass spectrometry platforms and artificial intelligence for data interpretation.
Protein microarrays offer a high-throughput screening technology that has multiple applications including clinical diagnostics or drug discovery. They can be used to develop high-throughput assays to assess protein interactions inside a biological sample or to assess expression patterns, which can allow advancements such as non-invasive testing or facilitate precision medicine.
The main end users are biopharmaceutical and biotechnology companies, academic and research institutes, hospitals, and clinical & diagnostic laboratories. These end users utilize proteomics in diagnostics, drug development, and personalized healthcare.
Proteomics research and diagnostics require sophisticated laboratory analytic instruments such as mass spectrometers, chromatography systems, and microarray systems; infrastructure for bioinformatics, and bioinformatics for high-performance computing and personnel with the expertise to manage and extract information from large and complex data sets.
Academic institutions often have very innovative research on disease biomarkers, disease proteins and protein interactions, and therapeutic targets. Some of the centers in Germany, Japan, and the U.S. are advancing proteomics in support of neurodegenerative and regenerative medicine.
Diagnostic laboratories have both routine and specialized disease testing using proteomics, to support ongoing screening for disease, including cancer and chronic diseases. They can be used for new kinds of multiplex, non-invasive proteomic assays to assist with early stage detection, risk stratification, grading, and treatment allocation.
AI detects disease-trajectories in complex-proteomic datasets allowing for faster analysis which mean less human error with concurrent improvements in the rates of biomarker discovery. AI also enables predictive diagnostics, guiding towards scalable solutions for precision medicine.
The greatest potential for growth and impact involves the integration of proteomics with genomic and metabolomic data, providing improved prediction of disease states, early diagnosis of disease, and truly personalized therapies. As well, the incorporation of AI-powered multi- omics models are transforming healthcare at all levels from a reactive approach to a primarily preventive stance at a global level.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
Report ID: SQMIG35H2340
sales@skyquestt.com
USA +1 351-333-4748